Critically ill patients hospitalized with COVID-19 — particularly those who develop ARDS — may also experience an opportunistic aspergillosis superinfection.
Influenza hospitalizations were decreased among people with diabetes when vaccines were received in multiple influenza seasons.
Study reveals no evidence for an association between first-trimester vaccination and major malformations or congenital heart defects in infants.
A team of investigators conducted a retrospective cohort study to determine the risk of subdeltoid bursitis associated with the administration of the influenza vaccine.
A team of investigators report on the findings from a randomized controlled trial of 3 enhanced influenza vaccines and a standard-dose vaccine in older adults.
In response to the COVID-19 pandemic, New York State implemented a series of community mitigation strategies, and monitoring approaches are needed to assess the effect of these interventions.
Cell-cultured quadrivalent influenza vaccines may have greater effectiveness compared with standard, egg-derived quadrivalent influenza vaccines.
Targeting the elderly (individuals aged 65 years) for influenza vaccination may not decrease hospitalization or mortality rates in this population.
In laboratory-confirmed cases of COVID-19, patients with any comorbidities have experienced poorer clinical outcomes compared with those without comorbidities.
Hospitalized patients withCOVID-19 had higher proportions of nonproductive cough, fatigue, and gastrointestinal symptoms as well as lower severity of illness scores compared with patients with H1N1 influenza.
The observed intra-seasonal decreases of measured influenza vaccine effectiveness was only partially accounted for by leaky vaccine bias.
Wearing face masks could be slightly protective against primary infection with influenza-like illness from casual community contact.
Hospitalization due to influenza leads to a high likelihood of readmission within 30 days and 1 year with cardiovascular, respiratory, and infectious etiologies being the most common.
The adjuvanted, broad-spectrum influenza vaccine FLU-v was found to be immunogenic and merits phase 3 development to explore efficacy.
Researchers determined the risk for Guillain-Barré Syndrome following seasonal influenza vaccination in a real-world study.
Baloxavir inhibits the endonuclease activity of the polymerase acidic protein resulting in inhibition of influenza virus replication.
Implementation of an influenza immunization program increased vaccinations rates from 44% to 57% the following year.
Early neuraminidase inhibitor therapy may result in better outcomes in patients hospitalized with influenza B-related pneumonia.
The FDA has approved Fluad Quadrivalent for active immunization in patients 65 years of age and older against influenza disease caused by influenza virus subtypes A and types B contained in the vaccine.
No difference was seen in the risk for serious neuropsychiatric events in patients who received oseltamivir in the 30 days after influenza diagnosis compared with those who did not.